CN104788411A - E-5-hydroxystyryl-1,3-difuronic acid phenolic ester and preparation method and application thereof - Google Patents
E-5-hydroxystyryl-1,3-difuronic acid phenolic ester and preparation method and application thereof Download PDFInfo
- Publication number
- CN104788411A CN104788411A CN201510177126.0A CN201510177126A CN104788411A CN 104788411 A CN104788411 A CN 104788411A CN 201510177126 A CN201510177126 A CN 201510177126A CN 104788411 A CN104788411 A CN 104788411A
- Authority
- CN
- China
- Prior art keywords
- preparation
- resveratrol
- trans
- verakanol derivative
- ethyl acetate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 Oc1cc(C=Cc(cc2)cc*2O)cc(O)c1 Chemical compound Oc1cc(C=Cc(cc2)cc*2O)cc(O)c1 0.000 description 2
- NZRBHFUIHBQVIK-AATRIKPKSA-N Oc1ccc(/C=C/c2cc(COC(c3ccc[o]3)=O)cc(OC(c3ccc[o]3)=O)c2)cc1 Chemical compound Oc1ccc(/C=C/c2cc(COC(c3ccc[o]3)=O)cc(OC(c3ccc[o]3)=O)c2)cc1 NZRBHFUIHBQVIK-AATRIKPKSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a resveratrol derivative of which the structural formula is shown in the description and also discloses a preparation method of the resveratrol derivative, as well as application of the resveratrol derivative to preparation of a medicine for treating breast cancer. The inhibitory activity IC50 value of the resveratrol derivative to breast cancer cells MCF-7 reaches 42.7 [mu]M, so that the resveratrol derivative has a relatively strong breast cancer cell MCF-7 inhibiting effect.
Description
Technical field
The invention belongs to medicinal chemistry art, particularly relate to a kind of Verakanol derivative, specifically a kind of (E)-5-(hydroxystyrene based)-1,3-bis-furancarboxylic acid phenolic ester and preparation method and application.
Background technology
Trans-resveratrol is extensively present in various plants body, is a kind of phytoalexin that plant materials produces under the unfavourable condition such as uviolizing, the invasion of external germ, have numerous pharmacological actions, and it is low to have toxicity, the advantage that safety range is wide.Known trans-resveratrol have anti-oxidant, hypotensive, delay senility and antithrombotic effect.In recent years find that trans-resveratrol has obvious inhibit activities to kinds of experiments tumour, causes the common concern of people.
Comprise and can cause cell-cycle arrest to multiple mankind's trans-resveratrols such as leukemia, colorectal carcinoma, mammary cancer, prostate cancer, liver cancer and esophageal cancer cells, and differentiation-inducing or apoptosis.Trans-resveratrol is to the IC of typeⅡ pneumocyte strain to have pertinent literature to report
50it is 44.7 ± 0.06 μMs, to leukemia HL60 cell strain IC
50it is 5 ± 0.9 μMs, to the IC of Cervical Cancer HeLa Cells strain
50it is 22.5 ± 0.5 μMs and to human breast carcinoma MDA-MB-231 cell strain IC
50it is 20.5 ± 2.6 μMs.Separately have report trans-resveratrol to have restraining effect to human large intestine cancer HT-29 cell, meanwhile, trans-resveratrol can suppress hepatocellular carcinoma H22 and colorectal carcinoma SW480 clone cancer cells, causes prostatic cell PC-3 apoptosis.
In sum, trans-resveratrol not only has direct tumor-inhibiting action, also has antimutagenic and immunologic function enhancement, has the characteristic of low toxicity simultaneously.Trans-resveratrol chemistry (E)-3,4 ', 5-trihydroxy--toluylene by name.Structure is as follows:
Summary of the invention
The object of the present invention is to provide a kind of Verakanol derivative and preparation method and application, described this Verakanol derivative and preparation method and application solve the technical problem of the poor effect of pharmacological agent mammary cancer of the prior art.
The invention provides a kind of Verakanol derivative, shown in its structural formula as I:
。
Present invention also offers the preparation method of above-mentioned this Verakanol derivative, first take trans-resveratrol, trans-resveratrol is dissolved in methylene dichloride and triethylamine, described trans-resveratrol, the molecular volume ratio of methylene dichloride and triethylamine is 3 ~ 5mol:20 ~ 40L:1 ~ 2L, taking 2 furoyl chloride again adds in reaction vessel, stirring at room temperature reaction 1 ~ 2h, described trans-resveratrol and the mol ratio of 2 furoyl chloride are 1 ~ 2:2 ~ 4, after reactant completely dissolve, reaction solution concentrating under reduced pressure is except desolventizing, use organic solvent diluting again, use dilute hydrochloric acid and saturated common salt water washing respectively successively, dry filter, desolventizing is removed again with organic phase concentrating under reduced pressure, resistates silica gel column chromatography obtains compound (E)-5-(hydroxystyrene based)-1, 3-bis-furancarboxylic acid phenolic ester.
Further, the volume ratio of the eluent in described silica gel column chromatography, ethyl acetate and petroleum ether mixtures is 3:2, and in described ethyl acetate and petroleum ether mixtures, ethyl acetate and sherwood oil are arbitrary volume ratio.
Further, described organic solvent is ethyl acetate.
Further, the concentration of described dilute hydrochloric acid is 0.1 ~ 3mol/L.
Further, anhydrous sodium sulfate drying is adopted to filter.
The equation of above-mentioned reaction is as follows:
Present invention also offers the application of above-mentioned a kind of Verakanol derivative in the medicine of preparation treatment mammary cancer.
The present invention compares with prior art, and its technical progress is significant.The invention provides a kind of new Verakanol derivative---(E)-5-(hydroxystyrene based)-1,3-bis-furancarboxylic acid phenolic ester compound, biological activity determination shows that it has stronger restraining effect to breast cancer cell MCF-7, to the IC of breast cancer cell MCF-7
50value reaches 42.7 μMs, is the lead compound of potential anti-breast cancer medicines.
Accompanying drawing explanation
fig. 1 shows the graph of a relation of concentration of the present invention and breast cancer cell MCF-7 inhibiting rate.
Embodiment
Below in conjunction with specific embodiment, set forth the present invention further.These embodiments are interpreted as only being not used in for illustration of the present invention limiting the scope of the invention.After the content of having read the present invention's record, those skilled in the art can make various changes or modifications the present invention, and these equivalence changes and modification fall into the scope of the claims in the present invention equally.
Embodiment 1
A kind of preparation method of (E)-5-(hydroxystyrene based)-1,3-bis-furancarboxylic acid phenolic ester compound, specifically comprises the following steps:
Trans-resveratrol 0.684 g (3mmol) is added in the round-bottomed flask of appropriate volume, be dissolved in 20mL methylene dichloride and 1mL triethylamine, add 2 furoyl chloride 0.783 g (6mmol) again, this reaction mixture stirring at room temperature reaction 1.5h, after thin layer analyses detecting reactant completely dissolve, reaction solution concentrating under reduced pressure removes most of solvent, then uses diluted ethyl acetate, use dilute hydrochloric acid and saturated common salt water washing successively, anhydrous sodium sulfate drying filters.Organic phase concentrating under reduced pressure is except desolventizing, and resistates silica gel column chromatography (eluent: ethyl acetate/petroleum ether=2/1) obtains compound (E)-5-(hydroxystyrene based)-1,3-bis-furancarboxylic acid phenolic ester.
HRMS (ESI)
m/
z[M + H]
+: 339.0686
1H NMR (500 MHz, DMSO-d
6) δ 9.81 (s, 1H), 9.62 (s, 1H), 8.10 (s, 1H), 8.02 (t,
J= 6.7 Hz, 1H), 7.43 (d,
J= 8.5 Hz, 2H), 7.35 – 7.30 (m, 1H), 7.13 (d,
J= 16.3 Hz, 1H), 6.95 (d,
J= 16.7 Hz, 2H), 6.85 (s, 1H), 6.77 (d,
J= 8.5 Hz, 2H), 6.53 (s, 1H)
Embodiment 2
(E)-5-(hydroxystyrene based)-1,3-bis-furancarboxylic acid phenolic ester measures the restraining effect of breast cancer cell MCF-7:
MTT colorimetry: according to cell growth rate, the tumour cell being in logarithmic phase is inoculated in 96 well culture plates with 100 μ L/ holes, adherent growth adds concentration gradient medicine in 24 hours again, if 5 gradient concentrations (0,25,50,100,200 μ g/ml), each concentration establishes three wells.Tumour cell is at 37 DEG C, 5%CO
2cultivate 48h under condition, then discard nutrient solution, with PBS punching 2 ~ 3 times, then every hole adds the nutrient solution of 100 μ L containing 10%MTT, cultivates 4h, then sucks nutrient solution.Finally add the dimethyl sulfoxide (DMSO) in 100 μ L/ holes, detect in full-automatic multi-functional microplate reader and measure A value under OD492nm and 630nm wavelength, calculate inhibitory rate of cell growth.
Experiment data measured sees the following form, and by Plotting data inhibiting rate and concentration relationship figure, can obtain IC from Fig. 1
50value.
| Concentration μ g/ml | A mean value | Survival rate % |
| 0 | 0.514667 | 100 |
| 25 | 0.463667 | 90.09067 |
| 50 | 0.371333 | 72.15026 |
| 100 | 0.181667 | 35.29793 |
| 200 | 0.004667 | 0.906736 |
Test the inhibit activities of breast cancer cell MCF-7, (E)-5-(hydroxystyrene based)-1,3-bis-furancarboxylic acid phenolic ester is to the IC of breast cancer cell MCF-7
50value was 42.7 (numerical value represents, concentration unit μM with " mean value ± standard deviation "), and illustrating that this compound has stronger breast cancer cell MCF-7 restraining effect, is the potential drug of anti-breast cancer.
Claims (7)
1. a Verakanol derivative, shown in its structural formula as I:
。
2. the preparation method of this Verakanol derivative according to claim 1, it is characterized in that: first take trans-resveratrol, trans-resveratrol is dissolved in methylene dichloride and triethylamine, described trans-resveratrol, the molecular volume ratio of methylene dichloride and triethylamine is 3 ~ 5mol:20 ~ 40L:1 ~ 2L, taking 2 furoyl chloride again adds in reaction vessel, stirring at room temperature reaction 1 ~ 2h, described trans-resveratrol and the mol ratio of 2 furoyl chloride are 1 ~ 2:2 ~ 4, after reactant completely dissolve, reaction solution concentrating under reduced pressure is except desolventizing, use organic solvent diluting again, use dilute hydrochloric acid and saturated common salt water washing respectively successively, dry filter, desolventizing is removed again with organic phase concentrating under reduced pressure, resistates silica gel column chromatography obtains compound (E)-5-(hydroxystyrene based)-1, 3-bis-furancarboxylic acid phenolic ester.
3. the preparation method of this Verakanol derivative as claimed in claim 2, it is characterized in that: the volume ratio of the eluent in described silica gel column chromatography, ethyl acetate and petroleum ether mixtures is 3:2, in described ethyl acetate and petroleum ether mixtures, ethyl acetate and sherwood oil are arbitrary volume ratio.
4. the preparation method of this Verakanol derivative as claimed in claim 2, is characterized in that: described organic solvent is ethyl acetate.
5. the preparation method of a kind of Verakanol derivative as claimed in claim 2, is characterized in that: the concentration of described dilute hydrochloric acid is 0.1 ~ 3mol/L.
6. the preparation method of this Verakanol derivative as claimed in claim 2, is characterized in that: adopt anhydrous sodium sulfate drying to filter.
7. the application of a kind of Verakanol derivative according to claim 1 in the medicine of preparation treatment mammary cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510177126.0A CN104788411A (en) | 2015-04-15 | 2015-04-15 | E-5-hydroxystyryl-1,3-difuronic acid phenolic ester and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510177126.0A CN104788411A (en) | 2015-04-15 | 2015-04-15 | E-5-hydroxystyryl-1,3-difuronic acid phenolic ester and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104788411A true CN104788411A (en) | 2015-07-22 |
Family
ID=53553650
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510177126.0A Pending CN104788411A (en) | 2015-04-15 | 2015-04-15 | E-5-hydroxystyryl-1,3-difuronic acid phenolic ester and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104788411A (en) |
-
2015
- 2015-04-15 CN CN201510177126.0A patent/CN104788411A/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| 刘鲁明等: "《肿瘤科特色治疗技术》", 31 May 2010, 科学技术文献出版社 * |
| 杜成等: "白藜芦醇衍生物的合成及抑制宫颈癌HeLa细胞肿瘤活性", 《有机化学》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105237504B (en) | Nitrogenous analog derivative of myricetin and its preparation method and application | |
| CN103880707B (en) | STAT3 micromolecular inhibitor and application thereof | |
| CN102863376B (en) | N-substituent methyl-3,5-is two replaces benzal base-4-piperidone and Synthesis and applications | |
| CN103845315A (en) | Histone deacetylase inhibitor and preparation method and application thereof | |
| CN104610054B (en) | Caffeoyl hydroquinone ester and preparation method and application of caffeoyl hydroquinone ester in preparation of tyrosinase inhibitor | |
| CN106496065A (en) | A kind of o-phenylenediamine Schiff base derivatives and preparation method and application | |
| CN103102331B (en) | Pharmaceutical application of chalcone compound containing piperazine ring | |
| CN104788411A (en) | E-5-hydroxystyryl-1,3-difuronic acid phenolic ester and preparation method and application thereof | |
| CN104844560A (en) | (E)-3-hydroxy-5-(hydroxystyryl)thiophene-2-phenol sulfonate and preparation method and application thereof | |
| CN104844561A (en) | (E)-5-(hydroxystyryl)-1,3-dithiophene-2-phenol sulfonate and preparation method and application thereof | |
| CN104356043B (en) | One prepares the method for 5-(2-fluorophenyl)-1H-pyrroles's-3-formaldehyde | |
| CN104844527A (en) | (E)-5-(hydroxystyryl)-1,3-dipyrazine-2-phenol formate and preparation method and application thereof | |
| CN104844504A (en) | (E)-5-(hydroxystyryl)-1,3-dipyridine-2-phenol formate and preparation method and application thereof | |
| CN104844517A (en) | (E)-3-hydroxy-5-(hydroxystyryl)imidazole phenol acetate and preparation method and application thereof | |
| CN104844505A (en) | (E)-3-hydroxy-5-(hydroxystyryl)pyridine-2-phenol formate and preparation method and application thereof | |
| CN103086985A (en) | 2-[4-(quinoxaline-2-oxygroup) phenoxy] alkylamide and application thereof | |
| CN108129325A (en) | A kind of nitrogenous diphenyl ethylene derivatives of fluoro and its preparation method and application | |
| CN106967146B (en) | Oleanolic acid terazole derivatives and its preparation method and application | |
| CN106083646B (en) | Different Korean pine acylhydrazone and preparation method and application | |
| CN103012431B (en) | A kind of synthetic method of deuterated Tazobactam Sodium | |
| CN109232703A (en) | Containing 16- (1 '-aromatic radical -1 ', 2 ', 3 '-triazoles) methylene-androstane -17- ketone derivatives | |
| CN104771392A (en) | Histone deacetylase inhibitor and applications thereof | |
| CN104725372A (en) | Tetracyclic indole alkaloid derivative as well as preparation method and application thereof | |
| CN103450181B (en) | Medical application of 2-[4-(quinoxaline-2-oxy)phenoxy]amide | |
| CN104341438B (en) | Cupric coordination compound with (4,4)-topological structure and preparation method thereof and application can be formed |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150722 |
|
| WD01 | Invention patent application deemed withdrawn after publication |